Looking Back on 2019 in Rheumatology and What to Expect from 2020 Roy Fleischmann Commentary Open access 10 December 2019 Pages: 1 - 3
Cardiovascular Comorbidities in Psoriatic Disease Agnes SzentpeteryMuhammad HaroonOliver FitzGerald Review Open access 07 December 2019 Pages: 5 - 17
Autoimmunity and Inflammation Link to Cardiovascular Disease Risk in Rheumatoid Arthritis Daniel J. DeMizioLaura B. Geraldino-Pardilla Review Open access 18 December 2019 Pages: 19 - 33
Nonmedical Switching From Originators to Biosimilars: Does the Nocebo Effect Explain Treatment Failures and Adverse Events in Rheumatology and Gastroenterology? Roy FleischmannVipul JairathPaul Declerck Review Open access 16 January 2020 Pages: 35 - 64
Clinical, Economic, and Humanistic Burden Associated With Delayed Diagnosis of Axial Spondyloarthritis: A Systematic Review Esther YiAmit AhujaYujin Park Review Open access 21 January 2020 Pages: 65 - 87
Characterizing Disease Manifestations and Treatment Patterns Among Adults with Systemic Sclerosis: A Retrospective Analysis of a US Healthcare Claims Population Sara L. GaleHuong TrinhKhaled Sarsour Original Research Open access 16 November 2019 Pages: 89 - 99
Spebrutinib (CC-292) Affects Markers of B Cell Activation, Chemotaxis, and Osteoclasts in Patients with Rheumatoid Arthritis: Results from a Mechanistic Study Peter H. SchaferAlan J. KivitzGarth E. Ringheim Original Research Open access 13 November 2019 Pages: 101 - 119
Risk of Malignancies in Patients with Rheumatoid Arthritis Treated with Rituximab: Analyses of Global Postmarketing Safety Data and Long-Term Clinical Trial Data Paul EmeryDaniel E. FurstPatricia B. Lehane Original Research Open access 21 November 2019 Pages: 121 - 131
Retrospective Analysis of the Impact of Adalimumab Initiation on Corticosteroid Utilization and Medical Costs Among Biologic-Naïve Patients with Rheumatoid Arthritis Christina A. SpiveyKevin L. WinthropJunling Wang Original Research Open access 18 November 2019 Pages: 133 - 147
A Comparative Study to Assess the Efficacy, Safety, and Immunogenicity of YLB113 and the Etanercept Reference Product for the Treatment of Patients with Rheumatoid Arthritis Hisashi YamanakaNaoyuki KamataniDhananjay Bakhle Original Research Open access 12 December 2019 Pages: 149 - 163
Comparative Cost per Response for 4 Clinical Endpoints with Tocilizumab Monotherapy vs Adalimumab Monotherapy in a Head-to-Head Randomized Double-Blind Superiority Trial (ADACTA) in Patients with Rheumatoid Arthritis Jennie H. BestSteven C. VladJinglan Pei Original Research Open access 06 January 2020 Pages: 165 - 171
Filgotinib, a JAK1 Inhibitor, Modulates Disease-Related Biomarkers in Rheumatoid Arthritis: Results from Two Randomized, Controlled Phase 2b Trials Jacqueline M. TarrantRené GalienPeter C. Taylor Original Research Open access 07 January 2020 Pages: 173 - 190
Pharmacokinetics, Pharmacodynamics and Safety of Belimumab in Chinese Patients with Systemic Lupus Erythematosus: A Phase I, Open-Label Study Jing ZhangWeiguo WanPeiming Ma Original Research Open access 17 January 2020 Pages: 191 - 200
Characteristics and Symptom Severity of Patients Reporting Systemic Lupus Erythematosus in the PatientsLikeMe Online Health Community: A Retrospective Observational Study Elisabeth NymanTimothy VaughanCathy Emmas Original Research Open access 01 February 2020 Pages: 201 - 213
Comment on “A Randomized, Double-Blind, Non-inferiority Study of Febuxostat Versus Allopurinol in Hyperuricemic Chinese Subjects with or Without Gout” Kevin D. B. van LeeuwenArthur M. Bohnen Letter Open access 10 December 2019 Pages: 215 - 216
